Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor (ACO-MONITOR)

An Observational Study to Learn More About How Acceptable and Practical a Digital Remote Monitoring Tool (Luscii) is in People With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid in the heart muscle. This build-up makes the heart stiff and can lead to symptoms of heart failure, such as difficulty breathing, tiredness, swelling in the legs, and reduced ability to be physically active. ATTR-CM occurs in two forms: a hereditary (variant) type caused by changes in genes, and a wild-type form that usually develops with aging.

People living with ATTR-CM are usually cared for at specialist centers, which may require them to travel long distances for appointments. Because of this, visits may be infrequent, and sometimes people only see their doctor once a year. This can make it harder to notice if the disease is getting worse or if there are problems with following their treatment plan. As a result, important changes in health may go unnoticed for several months, which can be risky.

Remote monitoring offers a way for people living with ATTR-CM and their healthcare professionals to stay connected between clinic visits. Recent studies have shown that remote monitoring can help by making it easier to share health information, spot problems earlier, and support people to follow their treatment plans. This can lead to fewer hospital visits and better health outcomes.

Luscii is a digital remote monitoring tool designed to help people living with ATTR-CM and their healthcare professionals stay connected between clinic visits. Luscii has two main parts: Luscii contact, a smartphone app that allows secure messaging and video calls, and Luscii vitals, a clinical software system that organizes health data and can alert the healthcare team if there are changes that need attention. Luscii vitals is a CE-marked medical device used within its approved purpose and does not replace a doctor's judgement.

By making it easier to communicate and share information, Luscii aims to support earlier detection of problems, better management of ATTR-CM, and a more positive experience for people living with this condition.

The main purpose of this observational study, called ACO-MONITOR, is to learn how acceptable and practical Luscii is for people living with ATTR-CM and their healthcare professionals. The study will take place in Austria, Germany, and Italy at three specialist centers. About 60 adults with a diagnosis of hereditary or wild-type ATTR-CM will be invited to take part. There will be no treatments given as part of this study. Instead, participants will use the Luscii app and devices at home to track their health and share information with their healthcare professionals. The study team will provide training on how to use Luscii and will help participants get started.

The study team will look at:

• How quickly and how often participants and healthcare professionals use Luscii
• How long Luscii is used by each person
• How many times participants use Luscii after being reminded
• How easy Luscii is to use, based on questionnaires for both participants and healthcare professionals

The study will last about 18 months in total, including a 6-month period to invite participants and a 12-month follow-up period. During the study, the study team will:

• Support participants in using Luscii to share health information from home
• Monitor how often and how easily Luscii is used
• Ask participants and healthcare professionals about their experiences using Luscii, including what worked well and what could be improved
• Record any problems or technical issues with using Luscii By collecting this information, the researchers hope to learn if Luscii can help improve communication, support earlier detection of health problems, and make it easier for people living with ATTR-CM to manage their condition between clinic visits.

Study Overview

• Status: Not yet recruiting
• Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
• Intervention / Treatment: Device: Luscii

• Study Type: Observational
• Enrollment (Estimated): 60

Contacts and Locations

• Study Contact: Name: Bayer Clinical Trials Contact; Phone Number: (+)1-888-84 22937; Email: clinical-trials-contact@bayer.com

Study Locations

• Austria
  • Innsbruck, Austria, 6020
    • Medizinische Universität Innsbruck
• Germany
  • Heidelberg, Germany, 69120
    • Universitätsklinikum Heidelberg
• Italy
  • Pavia, Italy, 27100
    • Policlinico San Matteo di Pavia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Eligible participants will be invited by their treating physician and, after providing informed consent, will be observed for approx. 12 months. Patients with an established diagnosis of either wild-type or variant ATTR-CM can be enrolled. Evidence of assessment of all eligibility criteria by the physician or a delegate, as well as enrolment of a participant in the study should be documented in the participant medical records

Description

Inclusion Criteria:

• Adult (≥18 years at the date of signing the informed consent form (ICF)).
• Diagnosis of either wild-type or variant ATTR-CM.
• Treatment with a drug approved for ATTR-CM, including newly prescribed therapy at the initial visit.
• Signed ICF.
• Access to and basic ability to use a personal smartphone with internet connectivity sufficient to install and operate the Luscii contact application.

Exclusion Criteria:

• Participation in an investigational program with interventions outside of routine clinical practice.
• Patients who are unable to provide consent, including those whose consent would need to be given by a legal representative.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Wild-type or variant ATTR-CM participants; Participants will be enrolled after the decision to initiate the use of the digital remote monitoring tool, Luscii, as per standard use.

Device: Luscii; The Luscii tool (CE class IIa certification) will be utilized for remote monitoring of health data specific to ATTR-CM patients. Following the observational nature of the study, no additional interventions will be implemented beyond the standard use of the Luscii tool. Participants will use the Luscii tool continuously throughout the observational period, which is approximately 12 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acceptance of Luscii among medical professionals	Defined as their willingness to adopt and engage with the ATTR-CM-specific configuration of Luscii vitals and Luscii contact throughout the study period.	At baseline (initial visit), at 6 months and at 12 months
Acceptance of Luscii among participants with ATTR-CM	Defined as their willingness to adopt and engage with the ATTR-CM-specific configuration of Luscii contact throughout the observational period.	At baseline (initial visit), at 6 months and at 12 months
Feasibility of Luscii for medical professionals	Defined as the practicality of implementing the tool in real-world ATTR-CM care throughout the study period.	At baseline (initial visit), at 6 months and at 12 months
Feasibility of Luscii for participants with ATTR-CM	Defined as the practicality of using the tool in real-world settings throughout the observational period.	At baseline (initial visit), at 6 months and at 12 months
Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among participants	Measured by the Patient Experience Questionnaire	At baseline (initial visit), at 6 months and at 12 months
Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among medical professionals	Measured by the Healthcare Professional (HCP) Experience Questionnaire	At baseline (initial visit), at 6 months and at 12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Participant demographic characteristics: age	Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline (initial visit)	At baseline (initial visit)
Participant demographic characteristics: sex	Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline	At baseline (initial visit)
Participant demographic characteristics: race	Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline	At baseline (initial visit)
Clinical characteristics: National Amyloidosis Centre (NAC) Stage	Categorization of participants according to the NAC Stage into stages I, II, or III, with stage III indicating a higher risk of mortality	At baseline (initial visit)
Clinical characteristics: relevant comorbidities	ATTR-CM relevant comorbidities	At baseline (initial visit)
Number of patients who failed screening		At baseline (Initial visit)
Reason for screening failure		At baseline (Initial visit)
Treatment patterns with Acoramidis: ATTR-CM prior medications	Concomitant medications administered within the past 12 months before initial visit	At baseline (initial visit)
Treatment patterns with Acoramidis: ATTR-CM concomitant medications	Previously administered ATTR-CM related medications within the past 12 months before initial visit	At baseline (initial visit)

Collaborators and Investigators

• Sponsor: Bayer

Study record dates

Study Major Dates

• Study Start (Estimated): May 22, 2026
• Primary Completion (Estimated): November 22, 2027
• Study Completion (Estimated): December 22, 2027

Study Registration Dates

• First Submitted: April 23, 2026
• First Submitted That Met QC Criteria: April 23, 2026
• First Posted (Actual): April 29, 2026

Study Record Updates

• Last Update Posted (Actual): May 19, 2026
• Last Update Submitted That Met QC Criteria: May 18, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Remote monitoring, Digital health, ATTR-CM
• Other Study ID Numbers: 23127

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No